Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM225CWN | HER2amp | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 12098.154 | 1.0927 | 1.1910 | 0.9724 | |
| SUM225CWN | HER2amp | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 12098.154 | 0.9052 | 0.8052 | 0.9724 | |
| SUM225CWN | HER2amp | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 12098.154 | 0.8951 | 0.7846 | 0.9724 | |
| SUM225CWN | HER2amp | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 12098.154 | 0.7430 | 0.4735 | 0.9724 | |
| SUM225CWN | HER2amp | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 12098.154 | 0.1866 | -0.6442 | 0.9724 | |
| SUM225CWN | HER2amp | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 12098.154 | 0.1317 | -0.7514 | 0.9724 | |
| SUM229PE | TNBC | - | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 11058.154 | 0.9442 | 0.9458 | 2.0897 | |
| SUM229PE | TNBC | - | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 11058.154 | 0.9947 | 0.9949 | 2.0897 | |
| SUM229PE | TNBC | - | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 11058.154 | 0.9645 | 0.9657 | 2.0897 | |
| SUM229PE | TNBC | - | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 11058.154 | 0.9925 | 0.9928 | 2.0897 | |
| SUM229PE | TNBC | - | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 11058.154 | 0.8538 | 0.8543 | 2.0897 | |
| SUM229PE | TNBC | - | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 11058.154 | 0.6591 | 0.6383 | 2.0897 | |
| SUM229PE | TNBC | - | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 11058.154 | 0.3040 | 0.1312 | 2.0897 | |
| SUM229PE | TNBC | - | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 11058.154 | 0.1724 | -0.1377 | 2.0897 | |
| SUM229PE | TNBC | - | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 11058.154 | 0.0424 | -0.5592 | 2.0897 | |
| SUM52PE | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 10695.154 | 1.0952 | 1.1271 | 1.4756 | |
| SUM52PE | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 10695.154 | 0.9762 | 0.9676 | 1.4756 | |
| SUM52PE | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 10695.154 | 1.0373 | 1.0503 | 1.4756 | |
| SUM52PE | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 10695.154 | 0.9041 | 0.8679 | 1.4756 | |
| SUM52PE | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 10695.154 | 0.8359 | 0.7712 | 1.4756 | |
| SUM52PE | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 10695.154 | 0.4175 | 0.1066 | 1.4756 | |
| SUM52PE | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 10695.154 | 0.4361 | 0.1397 | 1.4756 | |
| SUM52PE | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 10695.154 | 0.2090 | -0.3077 | 1.4756 | |
| SUM52PE | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 10695.154 | 0.0071 | -0.9300 | 1.4756 | |
| SUM52PE | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 11852.154 | 1.0106 | 1.0165 | 1.2816 |